NCT06271265View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 29, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Postoperative Pain
Interventions
DRUG

EXPAREL

A single dose of EXPAREL Injectable Product via LIA

DRUG

bupivacaine

A single dose of 0.25% bupivacaine via LIA

Trial Locations (4)

27710

RECRUITING

Duke University Health System, Durham

63110

RECRUITING

St. Louis Children's Hospital (SLCH), St Louis

73104

RECRUITING

University of Oklahoma (OU) - Medical Center - The Children's Hospital, Oklahoma City

77030

RECRUITING

The University of Texas Health Science Center at Houston (UTHSC-H) - McGovern Medical School, Houston

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY

NCT06271265 - Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery | Biotech Hunter | Biotech Hunter